Mammalian Genome

, Volume 28, Issue 7–8, pp 377–382 | Cite as

Phenotyping first-generation genome editing mutants: a new standard?

  • Lydia Teboul
  • Stephen A. Murray
  • Patrick M. Nolan
Open Access
Article

Abstract

The unprecedented efficiency of the CRISPR/Cas9 system in genome engineering has opened the prospect of employing mutant founders for phenotyping cohorts, thus accelerating research projects by circumventing the requirement to generate cohorts using conventional two- or three-generation crosses. However, these first-generation mutants are often genetic mosaics, with a complex and difficult to define genetic make-up. Here, we discuss the potential benefits, challenges and scientific validity of such models.

Introduction

The Clustered Regularly Interspaced Short Palindromic Repeat/CRISPR associated 9 (CRISPR/Cas9) system is a powerful tool for genome engineering, supporting the rapid production of mutant animals for phenotyping (Wang et al. 2013). Indeed, the first publication showing the use of this RNA-guided endonuclease (RGEN) system in generating insertions/deletions (indels) or point mutations also illustrated the possibility of characterising mutant phenotypes in founder cohorts. Although the original article highlighted the diversity of individuals generated with a given set of single guide RNAs (gRNAs) in any mutagenesis experiment, the publication made no mention of mosaicism nor of rearranged homology-directed repair event in the animals derived from microinjection (F0s). Further studies showed that the CRISPR/Cas9 system can facilitate the generation of even more complex alleles (tagged and conditional alleles) when co-delivered with longer DNA donor sequences (Yang et al. 2013). This seminal work led to proposing RGEN as a means to accelerate genetic studies by generating cohorts of F0 that bear one or multiple mutant alleles, generating either null or point mutations, for phenotyping (Wang et al. 2013).

As use of the technology quickly propagated in biomedical research, it became apparent that a large proportion of F0 animals derived from the microinjection of CRISPR/Cas9 reagents are genetic mosaics, most likely because the RGEN-induced mutagenic events occur following embryo cleavages (Yen et al. 2014; Singh et al. 2015; Mianné et al. 2017). Furthermore, a third of indels in coding regions do not result in a frameshift and therefore, in many cases, do not alter protein function. In a survey of a total of 19 F0 animals from 10 different mutagenesis experiments employing pronuclear microinjection of Cas9 mRNA, sgRNA and donor oligonucleotides, we detected an average of 2.8 alleles per animal, based on PCR amplification and sequencing of genomic DNA extracted from ear biopsies. Adding to the complexity of mosaicism, we and others also described that rearranged alleles (“illegitimate repairs”, Mianné et al. 2016; “KI + indels”; Renaud et al. 2016) are also created in parallel with the correct integration of donor sequences by homology-directed repair (HDR).

Thus, although the CRISPR/Cas9 system can yield very high mutagenesis efficiency, the same process can produce animals with unpredictable and complex genetic make-up that may be difficult to fully unravel. We discuss here the validity of these founders as subjects for phenotypic investigations.

Mosaic and chimeric analysis

Transient transgenics are unintentional mosaic F0s (Wilkie et al. 1986) and have been very successfully employed to study the regulation of gene expression. Furthermore, genetic mosaics and chimeras are classic experimental subjects that have been employed in both Drosophila (reviewed in Perrimon 1998) and mouse (reviewed in Rossant and Spence 1998) genetic studies. Their use enables the dissection of cell autonomous and non-autonomous roles of genes and pathways. A mosaic animal is defined as an organism composed of genetically distinct cells derived from the same zygote, while a chimera, commonly used in mouse studies, is composed of genetically distinct cells from different zygotes, typically an ES cell and embryo donor. Amongst other fields, such paradigms are of great value in developing cancer study models (Wang et al. 2007 and comment by; Lozano and Behringer 2007). Indeed, soon after its description as a genome editing tool, CRISPR/Cas9 was used to generate mosaic tissues in zebrafish liver showing that Anxa4 is required for liver progenitor viability (Zhang et al. 2014).

However, the complexity of the genetic make-up is quite different in these two classes of model. Chimeric animals consist of two precisely defined cell populations (i.e. through morula aggregation or ES cell injection in blastocyst). In contrast, in animals obtained with CRISPR/Cas9, unpredictable and diverse outcomes arise from mutagenic events from 1-cell onwards through to subsequent cellular cleavages in embryos. In the latter case, each animal is likely to have a unique spectrum of alleles and/or variable contribution of each allele to the whole organism. Moreover, accurate and quantitative ascertainment of the allelic spectrum is challenging because of the diversity of potential outcomes. Given these challenges, we considered whether these new (and more complex) mosaic animals are appropriate models for phenotyping?

CRISPR/Cas9 F0 phenotyping

Early publications on CRISPR/Cas9-aided in vivo mutagenesis in mouse (Wang et al. 2013) and in zebrafish (Thomas et al. 2014; Ablain et al. 2015) indeed brought a proof to the principle that phenotypes can be observed in cohorts of founder animals. Given the speed and efficiency of CRISPR/Cas9 gene targeting, direct screening of F0 animals could be particularly desirable as it has the potential to reduce time, effort and cost substantially.

F0 modelling of developmental phenotypes

As mentioned above, anecdotal evidence from early CRISPR experiments indicated that founders could indeed display phenotypes depending on the overall efficiency of the experiment. Additionally, we and others have found that production of KO alleles for genes predicted or known to be embryonic lethal frequently results in fewer than expected live born pups, suggesting lethality of F0 founder animals. Conceivably, therefore, developmental phenotypes could be directly assessed in F0 embryos, providing a potentially rapid means for testing hypotheses. For example, Guimier et al. showed that direct mutagenesis of the mouse orthologue of MMP21 could recapitulate the left–right asymmetry defects (presenting as heterotaxy) and associated congenital heart defects (CHD) in F0 embryos, validating the discovery of this gene in multiple human CHD pedigrees (Guimier et al. 2015). In this case, the efficiency of mutagenesis and penetrance of phenotypes was quite high, and the authors additionally showed that both KO and KI/KO allelic combinations were obtained and displayed the mutant phenotype despite clear mosaicism in some of the specimens examined. F0 mutagenesis has also been applied to scenarios that are challenging to model using standard mouse breeding. For example, Liu et al. were able to establish the digenic aetiology of the closely linked genes Sap130 and Pcdha9 in development of hypoplastic left heart syndrome (HLHS). The mutant embryos were also mosaic, displaying a range of mutagenesis and mosaicism, together with complex CHD phenotypes (Liu et al. 2017). However, there was clear phenotypic enrichment in digenic specimens with high rates of mutagenesis, corroborated by other evidence that the two genes act synergistically to cause the HLHS phenotype. These two studies show that F0 phenotyping is feasible, although it is important to note that there are limitations to the interpretation of the results versus typical approaches to mouse mutagenesis.

F0 modelling in adult mice

To date, there are few incidences in the literature where F0 phenotyping screens of adult animals have been utilised. This may relate to confounds associated with mosaicism as discussed above, or could reflect the restricted applicability of F0 phenotyping experiments. For example, a high degree of mosaicism in F0 animals can be visualised by targeting Tyr in pigmented animals and studies have shown how extensive this might be in any targeting study (Yen et al. 2014). A number of additional factors may also contribute to the difficulties of F0 screening including the type of mutation that the researcher intends to generate (missense versus null), the inherent variability of the phenotype being studied and the predictions as to how many F0 animals need to be screened to confirm that a particular mutation has an associated phenotype. The latter is particularly relevant when considering phenotypes associated with brain and behavioural function. Given the incidence of mosaicism seen in CRISPR/Cas9 studies, brain region-specific mutations are potentially highly variable. Ultimately, the investigator may want to confirm the true nature of the mutation by testing phenotypes in subsequent generations.

The use of CRISPR/Cas9 F0 screens for behavioural studies has some parallels in earlier studies in chimeric animals although mosaicism adds a level of complexity. In such an experiment, for example, Low-Zeddies and Takahashi (2001) investigated circadian behaviour in chimeric mice combining cells from wild-type LacZ-positive animals and homozygous Clock LacZ-negative mutants. In addition, coat pigmentation was used to illustrate the extent of chimerism in the 137 mice generated. By investigating the degree of chimerism in the suprachiasmatic nucleus (SCN) of the hypothalamus, the central pacemaker for the circadian clock, they established that all three major circadian clock parameters (period, amplitude and phase shifting) are separable based on the pattern of cells that express the Clock mutation. Furthermore, they established that, even when some cells in the SCN express the Clock mutation, the animals are behaviourally wild-type, while the converse was also true. These findings would argue that, in CRISPR/Cas9 F0 screens where behavioural phenotype is being investigated, it is important to determine the extent and/or pattern of mosaicism in the relevant brain regions of all individuals and to reflect on whether the gene in question functions in a cell autonomous or non-autonomous manner. This chimeric analysis carried out by Low-Zeddies and Takahashi would also argue that large numbers of animals should be tested prior to establishing any genotype/phenotype associations, and that negative results (animals with a WT phenotype) are difficult or impossible to interpret. In investigating the effects of Mecp2 on behavioural rhythms, Tsuchiya et al. (2015) looked at just 4 CRISPR/Cas9 targeted F0 animals while they used an additional 8 animals to investigate molecular oscillations in the SCN. Although they demonstrated significant effects on one circadian parameter (amplitude) in both sets of animals, the study of Low-Zeddies and Takahashi would suggest that further investigations of mosaicism in the SCN of a larger population of F0 animals would be warranted.

Perhaps, the most substantive behavioural study of CRISPR/Cas9 F0 animals to date has used a combination of three gRNAs to ensure efficient biallelic knockout of target genes (Sunagawa et al. 2016). The strategy was used first on the Tyr gene to test the efficiency of the approach and then used to validate a high-throughput sleep screen by targeting genes whose null alleles have previously been shown to affect sleep parameters (Bmal1, Hcrt, Cry1/Cry2 double knockout, Per1/Per2 double knockout). Having confirmed a sleep phenotype in these positive controls, the group then proceeded to screen CRISPR/Cas9 F0 knockouts of a gene family (NMDA receptor family) for sleep deficits and identified Nr3a as a sleep gene candidate using this approach. In testing between 2 and 15 individuals for each gene they target, the study shows that direct screening of CRISPR/Cas9 F0 individuals can successfully identify mutants, thus validating the causality of the target gene. However, questions remain as to the universal applicability of the approach, considering the degree of technical investment required for the production and characterisation of mutants, the variability in genetic outcomes, and the numbers of animals generated compared to screens where the mutation has been inherited through the germline. Ultimately, careful consideration of the costs and time required relative to “traditional” approaches is needed.

On the other hand, in particular circumstances, genetic mosaicism can be advantageous: Screening of CRISPR/Cas9 F0 individuals can provide useful additional information on the function of genes and mutant alleles. A recent study attempting to introduce a missense mutation in mouse Eef1a2, for example, highlights the complexity of the outcome of the technology while enabling investigators to salvage some useful information from F0 animals (Davies et al. 2017). Homozygous null mutations in mice result in early postnatal lethality while dominant de novo missense mutations in humans, including G70S, are associated with developmental delay, intellectual disability and autism. Attempts using CRISPR/Cas9 to generate animals with a single G70S mutation failed while most F0 animals carried biallelic mutations including deletions and del/G70S compound alleles. While most of these F0 mice exhibited early postnatal lethality, the findings did confirm that the G70S mutant protein was essentially non-functional. Furthermore, 6 out of the 35 F0s generated showed clear evidence of mosaicism with a clear variability in the cellular neuronal phenotypes seen in multiple brain sections and disparities between tail genotypes and Eef1a2 expression in brain and muscle. Screens in F0 mice can also be used to investigate the effects of a mutation in specific cells or tissues and may represent a speedy alternative to using complex crosses to generate conditional mutants. This approach has been considered by Zhong et al. (2015) to investigate retinal dysfunction in mosaic F0s associated with Kcnj13 deletion. Nevertheless, however promising these studies might be, care must be taken in interpreting the results while considering the nature and extent of the individual cellular mosaicism.

Challenges and limitations of F0 phenotyping

From these examples, it is clear that phenotypes in F0 embryos or animals can be obtained and characterised, and that they can provide corroborating evidence for genotype–phenotype relationships. There are, however, limitations to this approach. Specifically, it is unclear if mutagenesis of genes that function in a cell autonomous or non-autonomous fashion will be equally likely to yield a phenotype. One can envision that mutating a gene for a secreted factor might display a dosage curve relative to the number of cells carrying the relevant mutation. By contrast, in the case of a gene required autonomously for cell growth, compensation by unmutagenised cells could affect the presentation of a phenotype. Unlike chimeric analysis where the cell of origin is marked, this compensation may be indistinguishable if only a few cells are mutagenised. Additionally, it is not possible to interpret the negative phenotypic presentation as the lack of phenotype could be due to incomplete editing, or compensation from unmutagenised cells as noted above. Moreover, given recent reports that variable expressivity and incomplete penetrance are a common feature of gene knockouts (Dickinson et al. 2016; Karp et al. 2017; Meehan et al. 2017), it would be difficult to establish the source of such variance in a genetically mosaic F0 embryo or animal.

As discussed above, it is evident that phenotypes from F0 mutagenesis can be observed and interpreted, while a lack of phenotype cannot. Therefore, the full realisation of the potential of F0 screening will require better methods both to determine and quantitate the alleles in each mutant. PCR and cloning-based approaches can identify the range of alleles, but cannot accurately quantitate the abundance of each allelic species. Methods employing high-throughput sequencing have been developed, but are cost prohibitive due to the use of multiple sequencing libraries (Tsai et al. 2015). Regional mosaicism (different allelic combinations in different tissues) is an additional potential caveat, but it is difficult to assess the extent to which these allelic combinations might contribute to any individual phenotype. Neither of these issues is intractable but simply requires concerted tool development effort. With future advancements, the ability to describe a dose curve of mutagenesis and relate this to phenotypic presentation could be quite powerful, providing in a single experiment an “allelic series” not available using standard approaches.

When are CRISPR/Cas9-generated mosaics appropriate experimental models?

CRISPR/Cas9 can generate complex mosaics of unpredictable genetic composition that are difficult to fully characterise. Nevertheless, these can be attractive models for studies as illustrated above. Ultimately, the validity of such an approach depends on the specific experimental context and the scope of the interpretations reported. Because negative data cannot be reliably interpreted (all F0s without phenotypes could potentially be false negatives), F0 mutagenesis can only function as a “rule in” screen but cannot inform the role of genes in a given process for which no phenotype is observed. This is in contrast to the large-scale KO phenotypic screen of the IMPC, where the lack of phenotype in a carefully controlled context can be interpreted as an affirmative claim of wild-type function (Dickinson et al. 2016). However, an F0 screen might have significant value as a tool to rapidly screen through a large number of candidate disease genes, allowing the investigator to identify individual candidates for deeper analysis. Given the recent growth in the number of putative disease causing variants, F0 screens could provide a compromise solution that balances the need for rapid validation with the understanding that there will be a significant false-negative rate.

Although CRISPR/Cas9 methods and technologies are relatively recent, published studies already predict that the effectiveness of an F0 screen will hinge on the consideration of numerous factors. Consequently, in designing an F0 screen, we propose that one pay particular attention to (i) the choice of control, (ii) the experimental feasibility, (iii) the adherence to the Reduction and Refinement principles and (iv) the reproducibility of the study: (i) F0 founders will generally be obtained from embryos of super-ovulated donor females, further manipulated and re-implanted in pseudo-pregnant foster females, processes that are not without an impact on the biology of the offspring (Ertzeid and Storeng 2001). Will wild-type animals obtained by natural mating constitute the appropriate baseline for the experiment or must mock-mutated animals be generated alongside mutants for phenotyping? (ii) The complete genetic characterisation of F0 mutants requires a heavy investment in terms of sequencing the multiple alleles represented in the mosaic. Furthermore, fully understanding the distribution of these genotypes throughout the body may not be feasible. Definitive association of a phenotype to a genotype may require confirmation employing germline transmitted mutations. (iii) What is the impact of these experimental choices viewed from the angle of the Reduction and Refinement principles? Even though the CRISPR/Cas9 system is increasingly efficient, generating whole mutant cohorts, and perhaps controls, will likely represent a heavier burden on animal welfare (including surgical intervention) compared to the generation of small numbers of founders and breeding, particularly in the case of more complex mutations that require homologous repair. Numbers may have to be further increased to accommodate the genetic variability of the mutant founder and its impact in terms of experimental “noise”. Finally, (iv) the use of CRISPR/Cas9-generated founders as experimental models raises questions for the reproducibility of the study, as it is unlikely that genetically identical (mosaic) animals will be generated upon re-injection of the CRISPR/Cas9 reagents. Particular attention will have to be paid to the detailed description of the methods for generation and validation of mutants, phenotype range and methods for evaluating the extent of mutagenesis and its correlation to phenotypic expressivity (Kilkenny et al. 2010).

In summary, CRISPR/Cas9-generated founders can be of great value in specific cases but they may not be suitable individuals to constitute for phenotyping cohorts for many other animal studies. Genetic variability, appropriate controls, animal welfare and reproducibility of experiments, as ever, have to be considered and will be impacted when choosing to phenotype first-generation RGEN-generated mutants. The choice of phenotyping genome-edited F0s remains an unusual one and requires a justification when preferred over the study of stable and well-validated mutant lines.

References

  1. Ablain J, Durand EM, Yang S, Zhou Y, Zon LI (2015) A CRISPR/Cas9 vector system for tissue-specific gene disruption in zebrafish. Dev Cell 32(6):756–764. doi:10.1016/j.devcel.2015.01.032 CrossRefPubMedPubMedCentralGoogle Scholar
  2. Davies FC, Hope JE, McLachlan F, Nunez F, Doig J, Bengani H, Smith C, Abbott CM (2017) Biallelic mutations in the gene encoding eEF1A2 cause seizures and sudden death in F0 mice. Sci Rep 7:46019. doi:10.1038/srep46019 CrossRefPubMedPubMedCentralGoogle Scholar
  3. Dickinson ME, Flenniken AM, Ji X, Teboul L, Wong MD, White JK, Meehan TF, Weninger WJ, Westerberg H, Adissu H, Baker CN, Bower L, Brown JM, Caddle LB, Chiani F, Clary D, Cleak J, Daly MJ, Denegre JM, Doe B, Dolan ME, Edie SM, Fuchs H, Gailus-Durner V, Galli A, Gambadoro A, Gallegos J, Guo S, Horner NR, Hsu CW, Johnson SJ, Kalaga S, Keith LC, Lanoue L, Lawson TN, Lek M, Mark M, Marschall S, Mason J, McElwee ML, Newbigging S, Nutter LM, Peterson KA, Ramirez-Solis R, Rowland DJ, Ryder E, Samocha KE, Seavitt JR, Selloum M, Szoke-Kovacs Z, Tamura M, Trainor AG, Tudose I, Wakana S, Warren J, Wendling O, West DB, Wong L, Yoshiki A; International Mouse Phenotyping Consortium; Jackson Laboratory; Infrastructure Nationale PHENOMIN, Institut Clinique de la Souris (ICS); Charles River Laboratories; MRC Harwell; Toronto Centre for Phenogenomics; Wellcome Trust Sanger Institute; RIKEN BioResource Center, MacArthur DG, Tocchini-Valentini GP, Gao X, Flicek P, Bradley A, Skarnes WC, Justice MJ, Parkinson HE, Moore M, Wells S, Braun RE, Svenson KL, de Angelis MH, Herault Y, Mohun T, Mallon AM, Henkelman RM, Brown SD, Adams DJ, Lloyd KC, McKerlie C, Beaudet AL, Bućan M, Murray SA (2016) High-throughput discovery of novel developmental phenotypes. Nature 537(7621):508–514. doi:10.1038/nature19356 CrossRefPubMedPubMedCentralGoogle Scholar
  4. Ertzeid G, Storeng R (2001) The impact of ovarian stimulation on implantation and fetal development in mice. Hum Reprod 16(2):221–225CrossRefPubMedGoogle Scholar
  5. Guimier A, Gabriel GC, Bajolle F, Tsang M, Liu H, Noll A, Schwartz M, El Malti R, Smith LD, Klena NT, Jimenez G, Miller NA, Oufadem M, Moreau de Bellaing A, Yagi H, Saunders CJ, Baker CN, Di Filippo S, Peterson KA, Thiffault I, Bole-Feysot C, Cooley LD, Farrow EG, Masson C, Schoen P, Deleuze JF, Nitschké P, Lyonnet S, de Pontual L, Murray SA, Bonnet D, Kingsmore SF, Amiel J, Bouvagnet P, Lo CW, Gordon CT (2015) MMP21 is mutated in human heterotaxy and is required for normal left-right asymmetry in vertebrates. Nat Genet 47(11):1260–1263. doi:10.1038/ng.3376 CrossRefPubMedGoogle Scholar
  6. Karp NA, Mason J, Beaudet AL, Benjamini Y, Bower L, Braun RE, Brown SDM, Chesler EJ, Dickinson ME, Flenniken AM, Fuchs H, Angelis MH, Gao X, Guo S, Greenaway S, Heller R, Herault Y, Justice MJ, Kurbatova N, Lelliott CJ, Lloyd KCK, Mallon AM, Mank JE, Masuya H, McKerlie C, Meehan TF, Mott RF, Murray SA, Parkinson H, Ramirez-Solis R, Santos L, Seavitt JR, Smedley D, Sorg T, Speak AO, Steel KP, Svenson KL; International Mouse Phenotyping Consortium, Wakana S, West D, Wells S, Westerberg H, Yaacoby S, White JK (2017) Prevalence of sexual dimorphism in mammalian phenotypic traits. Nat Commun 8:15475. doi:10.1038/ncomms15475 CrossRefPubMedPubMedCentralGoogle Scholar
  7. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, NC3Rs Reporting Guidelines Working Group, (2010) Animal research: reporting in vivo experiments: the ARRIVE guidelines. J Gene Med 12(7):561–563. doi:10.1002/jgm.1473 CrossRefPubMedGoogle Scholar
  8. Liu X, Yagi H, Saeed S, Bais AS, Gabriel GC, Chen Z, Peterson KA, Li Y, Schwartz MC, Reynolds WT, Saydmohammed M, Gibbs B, Wu Y, Devine W, Chatterjee B, Klena NT, Kostka D, de Mesy Bentley KL, Ganapathiraju MK, Dexheimer P, Leatherbury L, Khalifa O, Bhagat A, Zahid M, Pu W, Watkins S, Grossfeld P, Murray SA, Porter GA Jr, Tsang M, Martin LJ, Benson DW, Aronow BJ, Lo CW (2017) The complex genetics of hypoplastic left heart syndrome. Nat Genet. doi:10.1038/ng.3870 Google Scholar
  9. Low-Zeddies SS, Takahashi JS (2001) Chimera analysis of the Clock mutation in mice shows that complex cellular integration determines circadian behavior. Cell 105(1):25–42CrossRefPubMedPubMedCentralGoogle Scholar
  10. Lozano G, Behringer RR (2007) New mouse models of cancer: single-cell knockouts. Proc Natl Acad Sci USA 104(11): 4245–4246. doi:10.1073/pnas.0700173104 CrossRefPubMedPubMedCentralGoogle Scholar
  11. Meehan TF, Conte N, West DB, Jacobsen JO, Mason J, Warren J, Chen CK, Tudose I, Relac M, Matthews P, Karp N, Santos L, Fiegel T, Ring N, Westerberg H, Greenaway S, Sneddon D, Morgan H, Codner GF, Stewart ME, Brown J, Horner N, International Mouse Phenotyping Consortium, Haendel M Washington N, Mungall CJ, Reynolds CL, Gallegos J, Gailus-Durner V, Sorg T, Pavlovic G, Bower LR, Moore M, Morse I, Gao X, Tocchini-Valentini GP, Obata Y, Cho SY, Seong JK, Seavitt J, Beaudet AL, Dickinson ME, Herault Y, Wurst W, de Angelis MH, Lloyd KCK, Flenniken AM, Nutter LMJ, Newbigging S, McKerlie C, Justice MJ, Murray SA, Svenson KL, Braun RE, White JK, Bradley A, Flicek P, Wells S, Skarnes WC, Adams DJ, Parkinson H, Mallon AM, Brown SDM, Smedley D (2017) Disease model discovery from 3328 gene knockouts by The International Mouse Phenotyping Consortium. Nat Genet. doi:10.1038/ng.3901 PubMedCentralGoogle Scholar
  12. Mianné J, Chessum L, Kumar S, Aguilar C, Codner G, Hutchison M, Parker A, Mallon AM, Wells S, Simon MM, Teboul L, Brown SD, Bowl MR (2016) Correction of the auditory phenotype in C57BL/6 N mice via CRISPR/Cas9-mediated homology directed repair. Genome Med 8(1):16. doi:10.1186/s13073-016-0273-4 CrossRefPubMedPubMedCentralGoogle Scholar
  13. Mianné J, Codner GF, Caulder A, Fell R, Hutchison M, King R, Stewart ME, Wells S, Teboul L (2017) Analysing the outcome of CRISPR-aided genome editing in embryos: screening, genotyping and quality control. Methods 121–122:68–76. doi:10.1016/j.ymeth.2017.03.016 CrossRefPubMedGoogle Scholar
  14. Perrimon N (1998) Creating mosaics in Drosophila. Int J Dev Biol 42(3):243–247PubMedGoogle Scholar
  15. Renaud JB, Boix C, Charpentier M, De Cian A, Cochennec J, Duvernois Berthet E, Perrouault L, Tesson L, Edouard J, Thinard R, Cherifi Y, Menoret S, Fontanière S, de Crozé N, Fraichard A, Sohm F, Anegon I, Concordet JP, Giovannangeli C (2016) Improved genome editing efficiency and flexibility using modified oligonucleotides with TALEN and CRISPR-Cas9 nucleases. Cell Rep 14(9):2263–2272. doi:10.1016/j.celrep.2016.02.018 CrossRefPubMedGoogle Scholar
  16. Rossant J, Spence A (1998) Chimeras and mosaics in mouse mutant analysis. Trends Genet 14(9):358–363CrossRefPubMedGoogle Scholar
  17. Singh P, Schimenti JC, Bolcun-Filas E (2015) A Mouse Geneticist’s Practical Guide to CRISPR Applications 2014. Genetics 199(1):1–15. doi:10.1534/genetics.114.169771 CrossRefPubMedGoogle Scholar
  18. Sunagawa GA, Sumiyama K, Ukai-Tadenuma M, Perrin D, Fujishima H, Ukai H, Nishimura O, Shi S, Ohno R, Narumi R, Shimizu Y, Tone D, Ode KL, Kuraku S, Ueda HR (2016) Mammalian reverse genetics without crossing reveals Nr3a as a short-sleeper gene. Cell Rep 14(3):662–677. doi:10.1016/j.celrep.2015.12.052 CrossRefPubMedGoogle Scholar
  19. Thomas HR, Percival SM, Yoder BK, Parant JM (2014) High-throughput genome editing and phenotyping facilitated by high resolution melting curve analysis. PLoS ONE 9(12):e114632. doi:10.1371/journal.pone.0114632. (Erratum in: PLoS ONE 2015;10(2):e0117764)CrossRefPubMedPubMedCentralGoogle Scholar
  20. Tsai SQ, Zheng Z, Nguyen NT, Liebers M, Topkar VV, Thapar V, Wyvekens N, Khayter C, Iafrate AJ, Le LP, Aryee MJ, Joung JK (2015) GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol 33(2):187–197 doi:10.1038/nbt.3117 CrossRefPubMedGoogle Scholar
  21. Tsuchiya Y, Minami Y, Umemura Y, Watanabe H, Ono D, Nakamura W, Takahashi T, Honma S, Kondoh G, Matsuishi T, Yagita K (2015) Disruption of MeCP2 attenuates circadian rhythm in CRISPR/Cas9-based Rett syndrome model mouse. Genes Cells 20(12):992–1005. doi:10.1111/gtc.12305 CrossRefPubMedGoogle Scholar
  22. Wang W, Warren M, Bradley A (2007) Induced mitotic recombination of p53 in vivo. Proc Natl Acad Sci USA 104(11):4501–4505CrossRefPubMedPubMedCentralGoogle Scholar
  23. Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, Jaenisch R (2013) One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153(4):910–918. doi:10.1016/j.cell.2013.04.025 CrossRefPubMedPubMedCentralGoogle Scholar
  24. Wilkie TM, Brinster RL, Palmiter RD (1986) Germline and somatic mosaicism in transgenic mice. Dev Biol 118(1):9–18CrossRefPubMedGoogle Scholar
  25. Yang H, Wang H, Shivalila CS, Cheng AW, Shi L, Jaenisch R (2013) One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell 154(6):1370–1379. doi:10.1016/j.cell.2013.08.022 CrossRefPubMedPubMedCentralGoogle Scholar
  26. Yen ST, Zhang M, Deng JM, Usman SJ, Smith CN, Parker-Thornburg J, Swinton PG, Martin JF, Behringer RR (2014) Somatic mosaicism and allele complexity induced by CRISPR/Cas9 RNA injections in mouse zygotes. Dev Biol 393(1):3–9. doi:10.1016/j.ydbio.2014.06.017 CrossRefPubMedPubMedCentralGoogle Scholar
  27. Zhang D, Golubkov VS, Han W, Correa RG, Zhou Y, Lee S, Strongin AY, Dong PD (2014) Identification of Annexin A4 as a hepatopancreas factor involved in liver cell survival. Dev Biol 395(1):96–110. doi:10.1016/j.ydbio.2014.08.025 CrossRefPubMedPubMedCentralGoogle Scholar
  28. Zhong H, Chen Y, Li Y, Chen R, Mardon G (2015) CRISPR-engineered mosaicism rapidly reveals that loss of Kcnj13 function in mice mimics human disease phenotypes. Sci Rep 5:8366. doi:10.1038/srep08366. (Erratum in: Sci Rep 2015;5:9731)CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s) 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Lydia Teboul
    • 1
  • Stephen A. Murray
    • 2
  • Patrick M. Nolan
    • 3
  1. 1.The Mary Lyon CentreMRC Harwell InstituteDidcotUK
  2. 2.The Jackson LaboratoryBar HarborUSA
  3. 3.Mammalian Genetics UnitMRC Harwell InstituteDidcotUK

Personalised recommendations